tbuckley/cabot-search huggingface dataset:
FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.
Authors: Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Rosello Keranen, Ruwaida Begum, Gina Brown, Diana M. Tait, Andrew Wotherspoon, Janet Thomas, Jacqueline Rose Oates, Ian Chau
Journal: Journal of Clinical Oncology (2014)

3573 Background: FCγRIIa-H131R and FCγRIIIa-V158F SNPs have been reported to enhance the immune-mediated effects of monoclonal antibodies including cetuximab (C) in metastatic colorectal cancer (CRC). Although the importance of antibody-dependent cell mediated cytotoxicity could be potentially higher in the adjuvant setting, there are no data on the relationship between these SNPs and C in patients (pts) with early stage disease. We performed a pharmacogenomic analysis of EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± C in high-risk, locally advanced rectal cancer. Methods: SNP analysis was performed on DNA extracted from peripheral blood samples. Kaplan-Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms. Results: A blood sample was available for genotyping in 105/164 (64%) pts (CAPOX=54, CAPOX-C=51) who were representative of the study population. Baseline characteristics were evenly allocated between the two treatment arms. Twenty five (23.8%) were homozygous for FCγRIIa-131H, 52 (49.5%) heterozygous (131H/R), and 28 (26.7%) homozygous for 131R. 13 (12.4%) were homozygous for FCγRIIIa-158V, 48 (45.7%) heterozygous (158V/F), and 44 (41.9%) homozygous for 158F. No deviation from the Hardy-Weinberg equilibrium or association with tumour RAS status was observed. FCγRIIa-131R (HR 0.38, p=0.058) and FCγRIIIa-158F alleles (HR 0.21, p=0.007) predicted progression-free survival (PFS) in pts treated with C. In the CAPOX-C arm, carriers of both 131R and 158F alleles had a statistically significant improvement in PFS (5-yrs 78.4%, HR 0.22, p=0.002) and overall survival (OS) (5-yr 86.4%, HR 0.24, p=0.018) when compared to pts homozygous for 131H and/or 158V (5-yr PFS 35.7%, 5-yrs OS 57.1%). An interaction between C benefit and presence of 131R and 158F alleles was found for PFS (p=0.017) and remained significant after adjusting for prognostic variables (p=0.003). Conclusions: This is the first study investigating FCγRIIa and FCγRIIIa SNPs in early stage CRC pts treated with C. Our findings suggest an increased clinical benefit from C in this patient population in the presence of 131R and 158F alleles.
EFFECT OF VALVE OVERSIZING ON LEAFLET BENDING STRESS IN THE COREVALVE: AN IN VITRO STUDY
Authors: Viktoria Stanova, Anne-Sophie Zenses, Régis Rieu, Lionel Thollon, Lyes Kadem, Morgane A. Evin, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2017)
The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL.
Authors: Birgit Kainz, Martin Bilban, Medhat Shehata, Daniel Heintel, Dirk Kienle, Elisabeth Kroemer, Trang Le, Alexander Kroeber, Ilse Schwarzinger, Andreas Gleiss, Andreas Chott, Hartmut Doehner, Sabine Zoechbauer9, Gerwin Heller9, Christa Fonatsch, Alexander Gaiger, Stephan Stilgenbauer, Christoph Zielinski, Oswald Wagner, Ulrich Jaeger
Journal: Blood (2005)
MULTIMODALITY CORONARY IMAGING TO PREDICT PERIPROCEDURAL MYOCARDIAL NECROSIS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Authors: Takayuki Niida, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Masahiro Hoshino, Masao Yamaguchi, Masahiro Hada, Sadamitsu Ichijo, Rikuta Hamaya, Yoshinori Kanno, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
Comparison of neurotoxicity between fractionated ICE and infusional ICE for relapsed/refractory lymphoma
Authors: C. H. Lim, H. Chow, W. Ong, M. Tao, H. J. Ng
Journal: Journal of Clinical Oncology (2004)

6718 Background: Previously we reported a high incidence of severe neurotoxic adverse events related to ifosfamide (IFX) in lymphoma patients receiving short infusions of IFX. Prolonged infusions of IFX has been suggested to be associated with a decreased risk of neurotoxicity. Methods: All relapsed/refractory Hodgkin's and Non-Hodgkin's lymphoma patients who received either fractionated ICE (D1–3: IFX 2g/m2 over 2h with an equivalent dose of mesna over 12h, carboplatin [AUC=5 divided equally between 3 days; max=800mg] over 1h, etoposide 75mg/m2 over 2h) or infusional ICE (IFX 5g/m2 over 24h D2, carboplatin AUC=5 over 1h D2, etoposide 100mg/m2/d over 2h D1–3, mesna 7.5g/m2 over 36h D2) between July 2001 and November 2003 were reviewed. Results: Six of 19 patients (7 of 56 courses) receiving fractionated IFX developed neurotoxicity. Symptoms included one or more of the following: confusion (n=7), mood alterations (n=3), hallucinations (n=2), and somnolence (n=4). Of these, grade 3 toxicities occurred in 3 ...
Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
Authors: J. P. Kirkpatrick, J. J. Vredenburgh, A. Desjardins, S. Gururangan, K. B. Peters, S. T. Boulton, A. H. Friedman, H. S. Friedman, D. A. Reardon
Journal: Journal of Clinical Oncology (2009)

e13007 Background: Malignant glioma (MG), an incurable primary CNS tumor, is characterized by frequent aberrant activation of EGFR, VEGFR, and PDGFR. This study will determine the MTD and DLT of vandetanib (V), a once-daily, oral selective inhibitor of VEGFR and EGFR when combined with imatinib mesylate (IM), an inhibitor of multiple tyrosine kinases including PDGFR and hydroxyurea (H). Methods: Adult recurrent MG patients with ≤ 3 prior recurrences, KPS ≥ 60% and adequate organ function were stratified based on concurrent enzyme-inducing anticonvulsant use (EIAC). Both strata were independently escalated using a “3+3” design. H is administered at 500 mg BID while IM is administered at 500 mg BID for patients on EIAC and 400 mg QD for those not on EIAC. V is increased by 100 mg in successive cohorts beginning at 100 mg and 200 mg for patients not on and on EIAC, respectively. Evaluations were after every other 28-day cycle. Pharmacokinetics of V and IM were obtained on days 1 and 28 of cycle 1. Results: Twenty-six patients (grade 4 MG, n = 20; grade 3 MG, n = 6) have enrolled. Only 1 DLT (reversible grade 4 transaminase elevation; dose level 1) occurred among 22 non-EIAC patients and enrollment to this stratum is planned to continue at dose level 4. The MTD of V for patients on EIAC is 200 mg/day due to 2 of 3 patients developing grade 3 thrombocytopenia at the 300 mg/day dose level. Evidence of therapeutic benefit to date includes 1 partial response and 15 patients (58%) with stable disease for at least 4 weeks, including 4 patients for ≥4 months. Conclusions: Combination of V, IM, and H is well-tolerated in recurrent MG patients. Further accrual is ongoing and an update of outcome, toxicity, and pharmacokinetic analyses will be presented. No significant financial relationships to disclose.
The Triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid and Its Derivatives Inhibit Mitochondrial Lon Protease Activity: A Potential Novel Pathway for the Induction of Lymphoma Cell Death.
Authors: Steven H. Bernstein, Bin Lin, Shannon Hilchey, N. Villaluna, L. Chen, K. Madura, Kim Morse, Hollie Metcalf, Michael Andreeff, Paul S Brookes, Carolyn K Suzuki
Journal: Blood (2009)
Multiplatform profiling of a fibrolamellar carcinoma cohort.
Authors: James J. Harding, Sherri Z. Millis, Eileen Mary O'Reilly, Leonard Saltz, Ghassan K. Abou-Alfa, Alan P. Venook, Robert J. Mayer, Michael A. Choti, David Cosgrove
Journal: Journal of Clinical Oncology (2014)

e15125 Background: Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy that affects the young without underlying liver disease. The pathogenesis of FLC is largely unknown, though several potential drivers have been identified. Methods: Pathologically confirmed FLC cases referred to Caris Life Sciences were evaluated by DNA sequencing (Sanger or next generation sequencing using Illumina MiSeq panel of 45 cancer-associated genes), protein expression (immunohistochemistry [IHC]), and/or gene amplification (CISH or FISH). Results: 21 FLC cases were referred between 2009 and January 2014, including 14 women and 7 men, median age of 25 years. Hormone receptor (AR, ER, PR) aberrations by IHC or HER2 alterations by FISH were not observed in the 21 cases. BCRP and MRP1 were overexpressed (80% and 75%, respectively) by IHC. cMET protein was overexpressed in 29% of cases, while MGMT, PTEN and TS protein expression was low or absent in a large percentage of cases (55%, 90%, and 95%, respectively). 4 cases were sequenced for 45 cancer associated genes, and a single gene mutation, RB1 (c.381T>C), was identified in 1 case. CTNNB1 and TP53, genes typically altered in hepatocellular carcinoma, did not show any alterations in these patients. Conclusions: In this small series of FLC cases, no clear signature in regard to the origin of FLC could be identified. This enforces the need for collaborative efforts to help establish a large case series that may help shed a light on the potential drivers of FLC.
Dietary Pattern and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study
Authors: Marianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, Rene Costello, Johanna E Torfadottir, Bryndis E Birgisdottir, Debra Burton, Laufey Steingrimsdottir, Neha S Korde, Sham Mailankody, Gudny Eiriksdottir, Lenore J Launer, Tamara B Harris, Ola Landgren, Vilmundur Gudnason, Sigurdur Y Kristinsson
Journal: Blood (2016)
Prognostic impact of polymorphisms of caspase genes on survival in patients with operated invasive ductal breast cancer
Authors: H. Park, J. Jung, Y. Eun, J. Kim, Y. Chae, J. Kim, S. Sohn, J. Park, J. Yang, Y. Lee
Journal: Journal of Clinical Oncology (2009)

e22020 Background: Since the apoptosis induced by caspases may play a role in the prognosis of breast cancer, the present study analyzed the polymorphisms of caspase genes and their impact on the survival in patients with operated invasive ductal breast cancer. Methods: Two hundred eighty patients with breast cancer who underwent surgery with curative intent were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue, and 7 single nucleotide polymorphisms (SNPs) of 6 caspase genes were determined using a PCR-RFLP assay. Results: The median age was 49 (range, 24–82) years, and 157 (56.1%) patients were premenopause at the time of diagnosis. Thirty-six (12.9%) patients underwent breast-conserving surgery. Pathologic stages after surgery were as follows: stage I (n=86, 30.7%), stage II (n=129, 46.1%), and stage III (n=63, 22.5%). Among the target SNPs, CASP6 (rs2301717, +5095G&gt;T) and CASP7 (rs11593766, +11G&gt;T) were found to correlate with relapse-free survival (RFS) after curative surgery in an univariate analysis adjusted to age, stage, histological grade, and the immunohistochemical expression of estrogen receptor and HER2. Meanwhile, multivariate analysis showed that the combined GT and TT genotype of CASP6 (rs2301717) was associated with a better RFS than the GG genotype (HR=0.39; 95% CI=0.19–0.79; p=0.009). However, there was no significant association with overall survival. Conclusions: The CASP6 (rs2301717) polymorphism may be considered as a possible prognostic factor for survival in patients with operated invasive breast cancer. No significant financial relationships to disclose.
VASCULAR FUNCTION OF CONDUIT ARTERIES IS ASSOCIATED WITH PROGRESS OF DIABETIC RETINOPATHY IN TYPE 2 DIABETES
Authors: Alexis S. Antonopoulos, Nikolaos Gouliopoulos, Gerasimos Siasos, Evangelos Oikonomou, Theodosia Konsola, Georgia Siasou, Manolis Vavuranakis, Nikolaos Tentolouris, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
Experience with Pegylated Interferon α-2a in 30 Patients Diagnosed with Hematologic Neoplasms
Authors: Adile Begum Bahcecioglu, Sezgin Etgul, Tuncay Aslan, Muruvvet Seda Aydın, Umit Yavuz Malkan, Mufide Okay, Evren Ozdemir, Rafiye Ciftciler, Hakan Goker, Yahya Buyukasik
Journal: Blood (2016)
Phase I/II study of irinotecan, UFT, and leucovorin with hepatic arterial infusion in colorectal cancer patients with unresectable liver metastases: Preliminary results
Authors: T. Yamaguchi, H. Matsumoto, K. Takahashi, M. Yasutome, T. Mori
Journal: Journal of Clinical Oncology (2007)

14549 Background: To determine the maximum-tolerated dose (MTD) and to evaluate the efficacy and tolerability of combination chemotherapy of irinotecan (CPT-11), UFT and leucovorin (LV) with hepatic arterial infusion (HAI) in colorectal cancer patients with unresectable liver metastases. Methods: Patients who had unresectable liver metastases from colorectal cancer were treated concurrently with intravenous CPT-11 on day1 of each 14-day treatment cycle with dose escalation, with orally UFT and LV on day 1–7 of each cycle, and with HAI of 5-FU on day 8–14 of each cycle. The primary objective of this phase I study was to determine the MTD of biweekly intravenous CPT-11 and UFT/LV with HAI of 5-FU. In the phase II study, the primary endpoint was to determine the response rate. Results: In the phase I study, the recommended dose of CPT-11 for phase II study was 140 mg/m 2 combined with UFT 300 mg/m 2 /day, LV 75 mg/body/day and 5-FU 2,000 mg/body/week. Sixteen patients were enrolled onto the phase II study. The six patients treated at the recommended dose during the phase I study also included in the phase II analysis (n = 22). Median number of liver metastases was 12 (range, 3 to 35). Median size of maximum diameter was 6.3 cm (range, 2.0 to 12.0 cm). The most common adverse event was neutropenia. The complete and partial response rate totaled 81.8%. Median survival time has not been reached yet. Eleven patients (50.0%) were ultimately able to undergo liver resection. Conclusions: The combination chemotherapy of CPT-11 and UFT/LV with HAI was safe, well tolerate and effective in current population of the patients with unresectable liver metastases from colorectal cancer. Updated toxicity and response data will be available in the spring of 2007. No significant financial relationships to disclose.
The effect of <i>SETD2</i> mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
Authors: Thai Huu Ho, Toni K. Choueiri, Anthony D'Amelio, James Hsieh, Paul L. De Souza, Keith C. Deen, Peter B. Langmuir, Yuan Liu, Robert J. Motzer
Journal: Journal of Clinical Oncology (2014)

4583 Background: Systematic sequencing studies of ccRCC identified loss of function mts in histone modifying enzymes such as SETD2 (15%). All SETD2 mts identified in pts disrupt expression of the SET domain, a conserved motif responsible for H3K36 tri-methyltransferase activity. In this study, we hypothesized that SETD2mts are associated with decreased H3K36me3 in ccRCC and we also investigate this association in relation with clinical outcome. Methods: Tumor samples were collected from consented subjects enrolled in a phase III trial of pazopanib vs. sunitinib (Motzer, NEJM 2013). Immunohistochemistry (IHC) for H3K36me3 was optimized with corresponding isotype controls. The Aperio platform was used to scan the slides for analysis of nuclear H3K36me3 levels using the CellMap image algorithm by Flagship Biosciences on 46 subjects with known SETD2 gene status by next generation sequencing. H3K36me3 signal was scored according to an H-score. Results: IHC shows a decrease in H3K36me3 staining in the tumor cells of SETD2 mutant (insertion/Deletion/Stop) while adjacent matched uninvolved kidney tissue retains H3K36me3 expression. Some SETD2 wild-type tumors also had decreased H3K36me3 staining, while the majority of these tumors displayed relatively robust, uniform staining for H3K36me3. Using an H-score cutoff of H≤29 (n=24) or >29 (n=22), we also observed significant differences in overall survival between patients with higher and lower H3K36me3 staining regardless of SETD2 mutation status (P=0.0454, Log-Rank). Conclusions: Loss of function SETD2 mts are associated with decreased H3K36me3 IHC. Loss of H3K36me3 staining in SETD2 wild-type RCC may reflect tumor heterogeneity or other post-translational mechanisms that promote dysregulation of SETD2 methyltransferase activity. Future studies will also examine the correlation of H3K36me3 with treatment response to contemporary therapy.
Circulating Endothelial Cells (CEC) and Angiogenesis-Related Factors in Multiple Myeloma (MM).
Authors: Dean A. Jobe, Krista E. Asp, Steven M. Callister, Craig E. Cole, Lori A. Meyer, Michelle A. Mathiason, Wayne A. Bottner, John P. Farnen, Ronald S. Go
Journal: Blood (2005)
A NEW PROGNOSIS SCORE TO PREDICT MORTALITY IN PATIENTS OVER 75 YEARS OLD UNDERGOING PRIMARY ANGIOPLASTY IN CARDIOGENIC SHOCK
Authors: Jose M. de la Torre Hernandez, Joan A. Gomez Hospital, Salvatore Brugaletta, Jose A. Baz, Armando Perez de Prado, Ramon Lopez Palop, Belen Cid, Tamara Garcia Camarero, Alejandro Diego, Federico Gimeno, Jose A. Fernandez Diaz, Juan Sanchis, Fernando Alfonso, Roberto Blanco, Javier Botas, Javier Navarro, Jose Moreu, Francisco Bosa, Jose M. Vegas, Jaime Elizaga, Antonio L. Arrebola, Jose R. Ruiz Arroyo, Jose A. Linares, Felipe Hernandez, Neus Salvatella
Journal: Journal of the American College of Cardiology (2017)
INNOVATIVE TECHNIQUE TO ACHIEVE HEMOSTASIS WITH LARGE BORE ACCESS FOR PERCUTANEOUS HEMODYNAMIC SUPPORT DEVICES
Authors: Ruchir Patel, Mahmoud Ali, Steven Nair, Mohammad Alqarqaz, Gerald Koenig, Mohammad Zaidan, Henry Kim, William O'Neill, Khaldoon Alaswad
Journal: Journal of the American College of Cardiology (2017)
Interaction of obesity and race in predicting recurrence rates after radical prostatectomy
Authors: D. J. Lee, C. Ritch, M. Desai, J. M. McKiernan
Journal: Journal of Clinical Oncology (2009)

5070 Background: Black men are twice as likely to die from prostate cancer compared to white men. Obese men are known to have higher mortality rates and recurrence rates, and blacks are 1.4 times as likely to be obese than white Americans. However, the relative contribution of BMI and race to biochemical failure (BCF) after radical prostatectomy (RP) has not been well-characterized. We examined the interaction of BMI and race in predicting BCF after RP. Methods: A retrospective analysis of the Columbia Urologic Oncology Database found that 3,736 consecutive men underwent RP between 1988 and 2008. 1,461 men had BMI and race data available. 213 (14.6%) were black men, 1,004 (68.7%) were white, 162 (11.1%) were Hispanic, and 82 (5.6%) were Asian. Overweight and obese men were defined as having a BMI &gt; 25 kg/m2 and a BMI &gt; 30 kg/m2, respectively. BCF was defined as a post-surgery PSA level &gt;0.2 ng/mL on &gt; 2 measurements. Cox regression methods were used to model the relationship between race, BMI and BCF. Results: The 1,461 men had a median age of 60 years, and median pre-operative PSA of 5.5. There was no significant difference in BMI among the four races (p = 0.58). The 5 year disease-free survival for black obese men was the lowest at 69%, compared to non-obese black (71%), obese white (80%), and non-obese white men (80%, p &lt; 0.001). BMI did not have a significant impact on BCF. After adjusting for preoperative PSA level, tumor stage, and Gleason sum, race remained an independent predictor of BCF (HR = 1.65, p = 0.04). An analysis assessing the effect of an interaction between race and BMI demonstrated that hazard ratios for increased BMI did not differ significantly by race. Black men who were normal, overweight and obese were 2.0, 3.0 and 2.5 times more likely than white men to have BCF in the respective weight categories, but the differences were not significant. Conclusions: Black race is an independent predictor of biochemical failure after adjusting for pathologic factors. The impact of BMI on BCF did not vary among different races. However, BMI does contribute to the accurate estimation of the risk of BCF. These findings suggest that elevated BMI does not affect the BCF rates of black men more than in other races, and that other factors may influence the racial variability in disease-free survival and BCF risk. No significant financial relationships to disclose.
IMPACT OF LEFT ATRIAL PRESSURE ON RECURRENCE OF ATRIAL FIBRILLATION 3 MONTHS AFTER CATHETER ABLATION
Authors: Martin Vandaele, Marc Badoz, Benjamin Bonnet, Marion Chatot, Romain Chopard, Marie-France Seronde, Francois Schiele, Nicolas Meneveau
Journal: Journal of the American College of Cardiology (2017)
Possible Autocrine Mechanism of Placenta Growth Factor / Vascular Endothelial Growth Factor Receptor Type 1 in Acute Lymphoblastic Leukemia with Philadelphia Chromosome.
Authors: Toshiko Ikai, Hiroshi Miwa, Masato Shikami, Akihito Hiramatsu, Noriaki Imai, Atsushi Satoh, Masato Itoh, Kazuhisa Miura, Akira Imamura, Hidetsugu Mihara, Kazuhiro Nishii, Masakazu Nitta
Journal: Blood (2004)
Use of the cumulative amount of serum-free light chains (sFLC) at diagnosis and PET2 for the early identification of high risk of treatment failure in Hodgkin lymphoma (cHL).
Authors: Rosaria De Filippi, Fortunato Morabito, Gaetano Corazzelli, Filippo Russo, Rosa Calemma, Giancarla Iaccarino, Stefania Crisci, Ferdinando Frigeri, Gaetana Capobianco, Francesco Volzone, Claudio Tripodo, Antonio Pinto
Journal: Journal of Clinical Oncology (2012)

8083 Background: Since early identification of patients (pts) at risk of failure is the mainstay of a risk-adapted therapy, we explored the prognostic impact of the sFLC assay in cHL, whose biology involves ongoing activation of polyclonal B-cells. Methods: Serum samples from 248 untreated cHL pts were tested by the Freelite assay. Median age was 32 yrs (r 15-85), males 47%, stages: I (5%), II (51%), III (17%), IV (27%); B-sympt. 60%, E-disease, 38%; bulky &gt;10 cm, 44%; ESR &gt; 65, 42%; IPS ≥3, 39%. Early unfavorable disease (GHLSG/ EORTC) was respectively found in 33% and 42% of cases. ABVD was given to 89% of pts. Results: Absolute FLC levels were summed into a sFLC(κ+λ) variable and ROC analysis indicated 57.1 mg/mL as the threshold to discriminate outcomes. CR rates were 96% and 67% for pts below and above the cutoff, respectively (p&lt;.0001). Cox univariate analysis disclosed a HR of 16.70 (95% CI, 8.5-32.9) of events for sFLC(κ+λ) ≥ 57.1 mg/mL, by far higher than for PET2 positivity (HR 10.8), PS &gt;1 (HR 4.2), IPS ≥3 (HR 2.8) and all other predictors (HR 0.54-2.4). In a multivariaye model only sFLC(κ+λ) and PET2 remained independent predictors. A dismal 8-yrs EFS characterized pts with sFLC(κ+λ) above threshold (20% vs 89%; Χ 2 119, p&lt;.0001). Pts with sFLC(κ+λ) below cutoff and a negative PET2 had an EFS of 93% as compared to 36% of those with sFLC(κ+λ) above cutoff or a positive PET2. Pts with sFLC(κ+λ) above cutoff and positive PET2, had the worse outcome with an EFS &lt;10% and a median survival &lt;12 mo.s (Χ 2 65.4; p&lt;.0001). sFLC assay was even more valuable in identifying poor risk pts within the early unfavorable category (5-yrs EFS &lt;25%, Χ 2 51 p&lt;.0001). By immunoistochemistry small B cells and plasmacytoid lymphocytes were identified as the main source of sFLC in HL tissues while a strong sFLC uptake by mast cells was documented. Conclusions: A cumulative amount of sFLC ≥57.1 mg/mL, is the strongest independent predictor of failure in cHL. Combining sFLC(κ+λ) and PET2 outcomes can timely discriminate poor risk pts subsets, who may benefit from upfront treatment escalation or early salvage. Our data also support that sFLC might endorse immunobiologic activities relevant to cHL pathobiology.
PHARMACOGENOMIC IMPLICATIONS OF RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Giovanni Peretto, Sara Baggio, Marco Magnoni, Nicole Cristell, Chiara Lanzani, Lorena Citterio, Paolo Manunta, Domenico Cianflone
Journal: Journal of the American College of Cardiology (2017)